OncoMatch/Clinical Trials/NCT07025018
Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations
Is NCT07025018 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies HMPL-306 for gliomas harboring idh1 and/or idh2 mutations.
Treatment: HMPL-306 — This study is a multicenter, randomized controlled Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of HMPL-306 in patients with gliomas harboring IDH1 and/or IDH2 mutations
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Biomarker criteria
Required: IDH1 mutation
Required: IDH2 mutation
Prior therapy
Cannot have received: IDH inhibitor
Previous treatment with IDH inhibitors
Lab requirements
Blood counts
Sufficient bone marrow and organ function
Kidney function
Sufficient bone marrow and organ function
Liver function
Sufficient bone marrow and organ function; history of clinically significant liver disease, including active infection with viral hepatitis, or other active hepatitis, alcoholic liver disease, cirrhosis, etc. [excluded]
Sufficient bone marrow and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07025018 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior IDH inhibitor disqualifies patients from enrollment.
Does this trial require IDH1?
Yes, IDH1 mutation is a required biomarker for enrollment.
Does this trial require IDH2?
Yes, IDH2 mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify